HIYORI
18.12.2020 10:02:12 CET | Business Wire | Press release
Hiyori Inc. (from Taito-ku, Tokyo, with Representative Director : Igarashi Takahiro), will release its first Online Puzzle Action game “Nosferatu Lilinor,” under the publishing brand “neon®”, for Nintendo Switch™ as a downloadable on Thursday, 24 December 2020, with additional features and improvements over its currently available Steam® version.
What is Nosferatu Lilinor?
A Retro-style, stage-by-stage, action-puzzle game. You will play as a vampire girl named “Lilinor” and lead her to the goal by solving puzzles with dreadfully high difficulty which will require timing as well as route planning. Challenging it will be, and death will be more common than expected.
Pack-full, new additional features!
As per requests by fans of the Steam® version, the following new features for the Nintendo Switch™ version have been added.
- The new, even-more-lenient ‘Very Easy’ mode. Most suitable for practicing.
- More cute and unique skins.
- Mid-stage alternative routes have been added, thus providing more choices for progression.
- Update some Graphics. World Map added.
- Zasha, the servant wolf, will be available to play in 2P mode to provide assistance to Lilinor.
Adjust the gameplay to your heart desires with these addition new features, new stages and new skins. Have fun!
Game Information
- Title: Nosferatu Lilinor
- Genre: High difficulty action-puzzle games
- Copyright: ©2019-2020 neon
- Released Date: Thursday, 24 December 2020
- Supporting Language: English, Chinese (Simplified Chinese/Traditional Chinese), Japanese, Korean, Spanish, German, French
- Price: € 14,53
- Pre-order discount: Yes (16, December 2020 00:00 (CET) - 23, December 2020 23:59 (CET))
- Playable Players: 2 Players per hardware
-
Suitable age : All ages (rating ages rank A by Cero)
IARC_USK 6
IARC_PEGI 3+
IARC_OFLCC(AGCB) G (General)
IARC_OFLC.NZ G (General) - Platform: Nintendo Switch™ (For download only)
- Official Webpage’s URL: http://hiyori-prd.com/lilinorsw/
- Official Twitter’s URL: https://twitter.com/NLilinorE/
“The image as you see is from the Development stage”
Company Information
Product’s Brand : Hiyori Inc.
Representative Director : Igarashi Takahiro
Address : 601 Kyou Wa no.1 Building, East Taito 1-29-4, Taito-Ku, Tokyo, JAPAN, 110-0016
Established : 20 January 2015
Business details : Entertainment software planning, Developing, Sale
URL : http://hiyori-prd.com/
[Press materials – Download]
https://www.hiyori-prd.com/lilinorsw/dl/neon_Press-specific_graphic_materials201216.rar
View source version on businesswire.com: https://www.businesswire.com/news/home/20201218005159/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
